Repurposing Therapeutics for Potential Treatment of SARS-CoV-2: A Review
Review
[키워드] Analysis
Antiviral
Baricitinib
benefit
camostat
Camostat mesylate
clinical trial
convalescent plasma
coronavirus
COVID-19
COVID-19 outbreak
Cytokine storm
disease
disease-specific treatment
effective therapy
Efficacy
epithelial cells
Evidence
Favipiravir
highlight
homology
humanized monoclonal antibodies
humanized monoclonal antibody
identify
IMPROVE
in vitro
include
MERS-CoV
Mortality
offer
pandemic coronavirus
passive immunity
Patient
patients with COVID-19
plasma
Potential
Remdesivir
repositioning
repurposing
Research
review
SARS-CoV
SARS-CoV-2
severe respiratory illness
shown
the SARS-CoV-2
the SARS-CoV-2 virus
therapeutic option
therapeutic options
therapeutic potential
Therapeutics
Tocilizumab
treat
Treatment
viral entry
[DOI] 10.3390/v12070705 PMC 바로가기 [Article Type] Review
[DOI] 10.3390/v12070705 PMC 바로가기 [Article Type] Review